Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholest…
Shares of Arrowhead Pharmaceuticals (ARWR) rallied sharply on Wednesday, closing up 19%, after the company released positive topline results from two key late-stage studies of its experimental drug plozasiran.The stock clocked its best day since late November and edged up further 1.5% after-hours.C…
Explore more price target data and ratings for Arrowhead Pharmaceuticals, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Arrowhead Pharmaceuticals, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research…
Shares of Arrowhead Pharmaceuticals (ARWR) surged more than 18% in pre-market trading on Wednesday and are on track to hit their highest levels in over five years, after the biotech firm reported positive topline results from two Phase 3 studies evaluating its hypertriglyceridemia therapy.Hypertrig…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia (sHTG), a condition that significantly increases the risk of acute pancreatitis (AP), which is asso…
Arrowhead Pharmaceuticals Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
(13:00 GMT) Arrowhead Pharmaceuticals Price Target Maintained With a $90.00/Share by Chardan Capital
Arrowhead reported plozasiran showed sustained triglyceride cuts and acceptable safety in its RNAi cardiometabolic program, per the company’s ongoing data readout.Arrowhead Pharmac
The cardiometabolic pipeline leverages RNAi technology to address both rare and prevalent lipid disorders, with REDEMPLO already launched and multiple late-stage programs advancing. Key upcoming milestones include pivotal data for plozasiran and zodasiran, and first human data for the dual-targetin…
The pipeline is advancing with late-stage studies for plozasiran and zodasiran, targeting severe hypertriglyceridemia and HoFH, respectively, and a dual-functional siRNA for mixed hyperlipidemia. Long-term data show robust efficacy and safety, with key data readouts and potential launches expected…
The cardiometabolic pipeline leverages RNAi technology to address both rare and prevalent lipid disorders, with key programs in severe hypertriglyceridemia and HoFH advancing toward pivotal data and regulatory milestones. Dual-targeting siRNA innovation aims to address mixed hyperlipidemia and resi…
A robust RNAi cardiometabolic pipeline is advancing, with plozasiran showing sustained triglyceride reductions and a strong safety profile, zodasiran demonstrating durable LDL-C lowering in HoFH, and ARO-DIMER-PA targeting dual lipid pathways. Key data readouts and regulatory filings are expected i…
